Login to Your Account



Other News To Note


Wednesday, June 19, 2013
• Civitas Therapeutics Inc., of Chelsea, Mass., said it received a $1 million grant from the Michael J. Fox Foundation for Parkinson's Research to support a Phase IIb trial of CVT-301, an inhaled formulation of levodopa that is being developed as an adjunct therapy to provide rapid relief from intermittent debilitating motor fluctuations, known as "off" episodes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription